High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D’amico; Giuseppina De Simone; Rosanna Cuccurullo; William G. Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro

doi:10.3390/biomedicines10061405

High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

Fabiana Cacace, Rossella Iula, Danilo De Novellis, Valeria Caprioli, Maria Rosaria D’amico, Giuseppina De Simone, Rosanna Cuccurullo, William G. Wierda, Kris Michael Mahadeo, Giuseppe Menna, Francesco Paolo Tambaro

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant trans-formation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.

Original language	English (US)
Article number	1405
Journal	Biomedicines
Volume	10
Issue number	6
DOIs	https://doi.org/10.3390/biomedicines10061405
State	Published - Jun 2022

Keywords

AML
outcome
pediatric
risk stratification
target therapy

ASJC Scopus subject areas

Medicine (miscellaneous)
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.3390/biomedicines10061405

Cite this

@article{4fb7e8684c634d18956c840c8af6eb56,

title = "High-Risk Acute Myeloid Leukemia: A Pediatric Prospective",

abstract = "Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant trans-formation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.",

keywords = "AML, outcome, pediatric, risk stratification, target therapy",

author = "Fabiana Cacace and Rossella Iula and {De Novellis}, Danilo and Valeria Caprioli and D{\textquoteright}amico, {Maria Rosaria} and {De Simone}, Giuseppina and Rosanna Cuccurullo and Wierda, {William G.} and Mahadeo, {Kris Michael} and Giuseppe Menna and Tambaro, {Francesco Paolo}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jun,

doi = "10.3390/biomedicines10061405",

language = "English (US)",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "6",

}

TY - JOUR

T1 - High-Risk Acute Myeloid Leukemia

T2 - A Pediatric Prospective

AU - Cacace, Fabiana

AU - Iula, Rossella

AU - De Novellis, Danilo

AU - Caprioli, Valeria

AU - D’amico, Maria Rosaria

AU - De Simone, Giuseppina

AU - Cuccurullo, Rosanna

AU - Wierda, William G.

AU - Mahadeo, Kris Michael

AU - Menna, Giuseppe

AU - Tambaro, Francesco Paolo

PY - 2022/6

Y1 - 2022/6

N2 - Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant trans-formation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.

AB - Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant trans-formation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.

KW - AML

KW - outcome

KW - pediatric

KW - risk stratification

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=85132565616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132565616&partnerID=8YFLogxK

U2 - 10.3390/biomedicines10061405

DO - 10.3390/biomedicines10061405

M3 - Review article

C2 - 35740427

AN - SCOPUS:85132565616

SN - 2227-9059

VL - 10

JO - Biomedicines

JF - Biomedicines

IS - 6

M1 - 1405

ER -

High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this